Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter
- 20 July 2005
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 181 (4) , 741-750
- https://doi.org/10.1007/s00213-005-0032-5
Abstract
Monoamine transporter inhibitor antidepressants have anxiolytic efficacy in man. However, preclinical data poorly reflect this, either because (1) few studies assess chronic antidepressant treatment in animal models, (2) antidepressants are anxiogenic after acute treatment; and (3) animal models of anxiety are insensitive to antidepressants. We address issues (1) and (2) and ascertain potential mechanisms mediating anxiolytic effects demonstrated. The effect of acute treatment with seven antidepressants covering the classes selective serotonin reuptake inhibitors, serotonin–noradrenaline reuptake inhibitors, noradrenaline reuptake inhibitors and tricyclic antidepressants were compared with the benzodiazepine, chlordiazepoxide, on the mouse zero maze, an unconditioned model of anxiety. Furthermore, citalopram, duloxetine, reboxetine and amitriptyline were assessed after chronic administration (10 mg/kg p.o., 21 days, twice daily) in this model. In mice treated chronically, (a) the hypothermic response to serotonin (5-HT)1A and 5-HT1B receptor ligands, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OHDPAT) and m-chlorophenyl piperazine (mCPP), respectively, was assessed and (b) serotonin transporter (SERT) and noradrenaline transporter (NET) densities in the cortex and hippocampus, respectively, were determined. None of the antidepressants were anxiolytic after acute treatment, although reboxetine, duloxetine and amitriptyline were anxiogenic. Only chronic treatment with duloxetine induced an anxiolytic effect, which was dissociable from nonspecific motor effects. Duloxetine reduced SERT density in the cortex by ∼75% compared to control, with no effect on NET density in the hippocampus. Citalopram and amitriptyline significantly reduced SERT density by ∼20%, whereas reboxetine selectively reduced NET density. All drugs reduced the hypothermic response to 8-OHDPAT and mCPP. Duloxetine was anxiolytic after chronic but not acute treatment, reflecting clinical experience with antidepressants in general. Duloxetine's anxiolytic-like profile may be ascribed to the considerable reduction in the density of the SERT in the cortex.Keywords
This publication has 51 references indexed in Scilit:
- Long term therapy of generalized anxiety disorderEuropean Psychiatry, 2004
- Requirement of Hippocampal Neurogenesis for the Behavioral Effects of AntidepressantsScience, 2003
- Pharmacological treatment of social anxiety disorder: A meta-analysisDepression and Anxiety, 2003
- Effects of the Selective Norepinephrine Reuptake Inhibitor Reboxetine on Norepinephrine and Serotonin Transmission in the Rat HippocampusNeuropsychopharmacology, 2001
- Mice plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after half‐life repeated administration. Comparison with acute administrationFundamental & Clinical Pharmacology, 1994
- Pharmacokinetics of venlafaxine andO-desmethylvenlafaxine in laboratory animalsXenobiotica, 1994
- Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulationsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1992
- [3H]Citalopram Binding to Brain and Platelet Membranes of Human and RatJournal of Neurochemistry, 1991
- Potential use of drugs modulating 5HT activity in the treatment of anxietyGeneral Pharmacology: The Vascular System, 1988
- Hypothermia induced by m-trifluoromethylphenylpiperazine or m-chlorophenylpiperazine: an effect mediated by 5-HT1B receptors?Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1988